相关实验视频

Updated: Jan 18, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

对于成人发病的神经退行性疾病的产前诊断测试

Maya Rawal^1,2, Stephanie Galloway^1,3, Michelle E Florido^1,4

¹Program in Genetic Counseling, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Prenatal diagnosis

|May 24, 2025

概括

大多数美国机构缺乏针对成人发病神经退行性疾病 (AOND) 的产前诊断测试 (PND) 的指导方针. 需要国家指导方针来应对伦理挑战,并标准化对AOND PND的护理.

科学领域:

医学遗传学医学遗传学
神经科学是一个神经科学.
公共卫生公共卫生

背景情况:

针对成人发病的神经退行性疾病 (AOND) 的产前诊断测试 (PND) 提出了独特的伦理和临床挑战.
美国AOND PND的现有机构实践和指导方针没有得到充分的记录.

研究的目的:

调查美国医疗保健机构中PND for AOND的当前做法和指导方针.
确定共识,差异和需求,确定国家准则的必要性.

主要方法:

通过关键的遗传学和母胎医学协会,向专业人士分发了一份问卷.
总共有104个符合条件的答案中的50个被分析为与AOND PND相关的共同主题和实践.

主要成果:

80%的回答机构缺乏正式的协议或书面指导方针 AOND PND.
关键的挑战包括道德决策,结果的双重披露和利益相关者的价值差异.
100%的受访者认为国家指南是有益的.

结论:

由于缺乏标准化的机构协议,对AOND的PND国家指导方针存在重大需求.
确定共识和不确定性的领域可以为未来的国家实践指南的制定提供信息.

更多相关视频

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...